SEC Form SC 13D/A filed by Graybug Vision Inc. (Amendment)

SEC Form SC 13D/A filed by Graybug Vision Inc. (Amendment)

Recent Analyst Ratings for $GRAY

$GRAY Analyst Ratings

$GRAY Press Releases

$GRAY SEC Filings

$GRAY Leadership Updates

$GRAY Insider Purchases

$GRAY Large Ownership Changes

Chat with this insight

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Graybug Vision downgraded by SVB Leerink with a new price target

Graybug Vision downgraded by Needham

SVB Leerink reiterated coverage on Graybug Vision with a new price target

Fastest customizable press release news feed in the world

Graybug Announces Name and Trading Symbol Change

Graybug and CalciMedica Enter into Definitive Merger Agreement

Graybug Vision Reports Financial Results for the Three and Nine Months Ended September 30, 2022

Graybug Vision Inc. filed SEC Form 8-K: Regulation FD Disclosure

SEC Form EFFECT filed by Graybug Vision Inc.

SEC Form S-3 filed by Graybug Vision Inc.

Live Leadership Updates

Graybug Vision Appoints Dirk Sauer to Board of Directors

Graybug Vision Appoints Bettina Maunz as Chief People Officer, Expanding the Company’s Executive Team

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Sanderling Venture Partners Vi Lp bought $2,515,080 worth of shares (679,384 units at $3.70), increasing direct ownership by 35% to 946,744 units (SEC Form 4)

Middleton Fred A bought $2,515,080 worth of shares (679,384 units at $3.70) (SEC Form 4)

Wilson Robert N bought $1,670 worth of shares (506 units at $3.30), increasing direct ownership by 0.28% to 182,161 units (SEC Form 4)

This live feed shows all institutional transactions in real time.

2/8/24 5:55:57 PM ET

$GRAY

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $GRAY alert in real time by email

SC 13D/A 1 d455225dsc13da.htm SC 13D/A SC 13D/A

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington 20549

SCHEDULE 13D/A

Under the Securities Exchange Act of 1934

(Amendment No. 2)

CALCIMEDICA, INC.

(Name of Issuer)

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

38942Q 202

(CUSIP Number)

Valence Investments SPV IV, LLC

Valence Investments SPV V, LLC

Valence Investments SPV VI, LLC

Eric Roberts

Rachel Leheny

590 Madison Avenue, 21^st Floor

New York, NY 10022

(212) 521-4379

with copy to:

Evan Ng

Dorsey & Whitney LLP

167 Hamilton Avenue, Suite 200

Palo Alto, CA 94301

(650) 565-2252

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

January 23, 2024

(Date of Event Which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

*	The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).


CUSIP No. 38942Q 202		SCHEDULE 13D		Page 2 of 10


1		NAMES OF REPORTING PERSON: Valence Investments SPV IV, LLC I.R.S. IDENTIFICATION NOS. OF ABOVE PERSON (ENTITIES ONLY):
2		CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS): (a) ☐ (b) ☐
3		SEC USE ONLY:
4		SOURCE OF FUNDS (SEE INSTRUCTIONS): OO
5		CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e): ☐
6		CITIZENSHIP OR PLACE OF ORGANIZATION: Delaware


NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	7	SOLE VOTING POWER: 0
	8	SHARED VOTING POWER: 356,989 (See Item 5)
	9	SOLE DISPOSITIVE POWER: 0
	10	SHARED DISPOSITIVE POWER: 356,989 (See Item 5)

¹	The calculation of percentage ownership is based on a total of 10,257,077 shares of Issuer common stock as of January 25, 2024, as set forth In the Issuer’s Registration Statement on Form S-3 filed with the SEC on January 31, 2024.


CUSIP No. 38942Q 202		SCHEDULE 13D		Page 3 of 10


1		NAMES OF REPORTING PERSON: Valence Investments SPV V, LLC I.R.S. IDENTIFICATION NOS. OF ABOVE PERSON (ENTITIES ONLY):
2		CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS): (a) ☐ (b) ☐
3		SEC USE ONLY:
4		SOURCE OF FUNDS (SEE INSTRUCTIONS): OO
5		CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e): ☐
6		CITIZENSHIP OR PLACE OF ORGANIZATION: Delaware


NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	7	SOLE VOTING POWER: 0
	8	SHARED VOTING POWER: 86,098² (See Item 5)
	9	SOLE DISPOSITIVE POWER: 0
	10	SHARED DISPOSITIVE POWER: 86,098² (See Item 5)

²	Includes 66,228 shares of common stock and 19,870 immediately exercisable warrants to purchase common stock at an exercise price of $27.94 per share received pursuant to the Merger Agreement.

³	The calculation of percentage ownership is based on a total of 10,257,077 shares of Issuer common stock as of January 25, 2024, as set forth In the Issuer’s Registration Statement on Form S-3 filed with the SEC on January 31, 2024.


CUSIP No. 38942Q 202		SCHEDULE 13D		Page 4 of 10


1		NAMES OF REPORTING PERSON: Valence Investments SPV VI, LLC I.R.S. IDENTIFICATION NOS. OF ABOVE PERSON (ENTITIES ONLY):
2		CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS): (a) ☐ (b) ☐
3		SEC USE ONLY:
4		SOURCE OF FUNDS (SEE INSTRUCTIONS): OO
5		CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e): ☐
6		CITIZENSHIP OR PLACE OF ORGANIZATION: Delaware


NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	7	SOLE VOTING POWER: 0
	8	SHARED VOTING POWER: 316,109 (See Item 5)
	9	SOLE DISPOSITIVE POWER: 0
	10	SHARED DISPOSITIVE POWER: 316,109 (See Item 5)

⁴	The calculation of percentage ownership is based on a total of 10,257,077 shares of Issuer common stock as of January 25, 2024, as set forth In the Issuer’s Registration Statement on Form S-3 filed with the SEC on January 31, 2024.


CUSIP No. 38942Q 202		SCHEDULE 13D		Page 5 of 10


1		NAMES OF REPORTING PERSON: Eric W. Roberts I.R.S. IDENTIFICATION NOS. OF ABOVE PERSON (ENTITIES ONLY):
2		CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS): (a) ☐ (b) ☐
3		SEC USE ONLY:
4		SOURCE OF FUNDS (SEE INSTRUCTIONS): PF
5		CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e): ☐
6		CITIZENSHIP OR PLACE OF ORGANIZATION: United States


NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	7	SOLE VOTING POWER: 376,264⁵
	8	SHARED VOTING POWER: 759,196⁶ (See Item 5)
	9	SOLE DISPOSITIVE POWER: 376,264⁵
	10	SHARED DISPOSITIVE POWER: 759,196⁶ (See Item 5)

⁵

Includes 111,373 shares of common stock held directly by Mr. Roberts, 51,778 shares of common stock held in individual retirement accounts for the benefit of Mr. Roberts, 119,885 Employee Stock Options to purchase common stock at an exercise price ranging from $3.25 to $17.34, and 93,228 warrants to purchase common stock at an exercise price ranging from $5.36 to $10.42 per share.

⁶

Includes 19,870 warrants to purchase common stock at an exercise price of $27.94 held by Valence Investments SPV V, LLC, 356,989 shares of common stock held by Valence Investments SPV IV, LLC, 66,228 shares of common stock held by Valence Investments SPV V, LLC, and 316,109 shares of common stock held by Valence Investments SPV VI, LLC. Mr. Roberts is a co-founder and managing director of Valence Investments SPV IV, LLC, Valence Investments SPV V, LLC, and Valence Investments SPV VI, LLC.

⁷	The calculation of percentage ownership is based on a total of 10,257,077 shares of Issuer common stock as of January 25, 2024, as set forth In the Issuer’s Registration Statement on Form S-3 filed with the SEC on January 31, 2024.


CUSIP No. 38942Q 202		SCHEDULE 13D		Page 6 of 10


1		NAMES OF REPORTING PERSON: A. Rachel Leheny I.R.S. IDENTIFICATION NOS. OF ABOVE PERSON (ENTITIES ONLY):
2		CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS): (a) ☐ (b) ☐
3		SEC USE ONLY:
4		SOURCE OF FUNDS (SEE INSTRUCTIONS): PF
5		CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e): ☐
6		CITIZENSHIP OR PLACE OF ORGANIZATION: United States


NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	7	SOLE VOTING POWER: 404,114⁸
	8	SHARED VOTING POWER: 759,196⁹ (See Item 5)
	9	SOLE DISPOSITIVE POWER: 404,114⁸
	10	SHARED DISPOSITIVE POWER: 759,196⁹ (See Item 5)

⁸

Includes 109,926 shares of common stock held directly by Ms. Leheny, 1,000 shares of common stock held by Ms. Leheny’s spouse, 202,102 Employee Stock Options to purchase common stock at an exercise price ranging from $2.44 to $17.34, and 91,086 warrants to purchase common stock at an exercise price ranging from $5.36 to $7.15 per share.

⁹

Includes 19,870 warrants to purchase common stock at an exercise price of $27.94 held by Valence Investments SPV V, LLC, 356,989 shares of common stock held by Valence Investments SPV IV, LLC, 66,228 shares of common stock held by Valence Investments SPV V, LLC, and 316,109 shares of common stock held by Valence Investments SPV VI, LLC. Ms. Leheny is a co-founder and managing director of Valence Investments SPV IV, LLC, Valence Investments SPV V, LLC, and Valence Investments SPV VI, LLC.

¹⁰	The calculation of percentage ownership is based on a total of 10,257,077 shares of Issuer common stock as of January 25, 2024, as set forth In the Issuer’s Registration Statement on Form S-3 filed with the SEC on January 31, 2024.


CUSIP No. 38942Q 202		SCHEDULE 13D		Page 7 of 10

Reference is hereby made to the statements on Schedule 13D originally filed with the Securities and Exchange Commission (the “SEC”) on March 30, 2023, as amended by Amendment No 1 filed with the SEC on November 22, 2023 (collectively, the “Schedule 13D”) which is incorporated by reference.

This Amendment No. 2 to the Schedule 13D filed, relating to the common stock, par value $0.0001 per share (the “Common Stock”) of CalciMedica, Inc., a Delaware corporation (the “Issuer”) amends and supplements certain of the items set forth therein.

Item 3. Source and Amount of Funds or Other Consideration.

Item 3 is hereby amended supplemented by adding the following at the end of Item 3:

On January 19, 2024, Mr. Roberts and Ms. Leheny, among other investors, entered into a Securities Purchase Agreement (“Purchase Agreement”) with Issuer. Pursuant to the terms of the Purchase Agreement, Mr. Roberts and Ms. Leheny each acquired from Issuer 91,086 common shares at $4.2665 per share, 45,543 common share purchase warrants exercisable at $5.36 per share until December 31, 2024, and 45,543 common share purchase warrants exercisable at $7.15 per share until December 31, 2026. Mr. Roberts and Ms. Leheny each used personal funds to acquire the securities.

The Purchase Agreement and the resulting issuance of the securities thereunder was approved by an independent committee of the Issuer’s Board of Directors.

Item 5. Interest in Securities of the Issuer.

Item 5 is hereby amended and supplemented as follows:

The Reporting Persons effected the following transactions in the Common Stock on the dates indicated, and such transactions are the only transactions in the Common Stock by the Reporting Persons in the sixty days preceding the filing of this Amendment, or since the last 13D filing, whichever is less:

Name

Nature of
Transaction

Date

Number of
Shares of
Common
Stock

Price per Share

Leheny

Acquired from Issuer

1/23/2024

91,086

4.2665

Roberts

Acquired from Issuer

2/5/2024

91,086

4.2665

Item 7. Material to be Filed as Exhibits.


Exhibit No.		Description

99.6		Form of Securities Purchase Agreement dated January 19, 2024 among Issuer and each purchaser identified on Exhibit A attached thereto (incorporated by reference from Exhibit 10.1 to Issuer’s 8-K filed January 22, 2024).


CUSIP No. 38942Q 202		SCHEDULE 13D		Page 8 of 10

Signatures

After reasonable inquiry and to the best knowledge and belief of the undersigned, such person certifies that the information set forth in this Statement with respect to such person is true, complete and correct.


	VALENCE INVESTMENTS SPV IV, LLC

Dated: February 8, 2024	By:	/s/ Eric Roberts
	Name:	Eric Roberts
	Title:	Manager

	VALENCE INVESTMENTS SPV V, LLC

Dated: February 8, 2024	By:	/s/ Eric Roberts
	Name:	Eric Roberts
	Title:	Manager

	VALENCE INVESTMENTS SPV VI, LLC

Dated: February 8, 2024	By:	/s/ Eric Roberts
	Name:	Eric Roberts
	Title:	Manager

	ERIC ROBERTS:

Dated: February 8, 2024	By:	/s/ Eric Roberts

	A. RACHEL LEHENY:

Dated: February 8, 2024	By:	/s/ A. Rachel Leheny

Get the next $GRAY alert in real time by email

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON:

356,989 (See Item 5)

CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS):

☐

Not Applicable

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11):

3.5%¹

TYPE OF REPORTING PERSON (SEE INSTRUCTIONS):

PN